The clear winner of our poll on antibody specificity was that antibodies have evolved to ignore HAS/IgG. I struggle with this, as I think it is too simple. Really, the way that antibodies rearrange to detect foreign antigens is open; there are no barriers to antibodies developing against self proteins. We probably should have used a different term than Chckpt Inb (checkpoint inhibition) as the second option, but this is the essence of why antibodies work well in matrices. Antibodies that develop to bind to self-targets within a biological matrix, such as human serum albumin or the Fc regions of IgG’s, undoubtedly do arise, but they are eliminated as dangerous. There are two systems, gratis – open development of antibodies against any target, and a counter-balancing system that detects and weeds out antibodies that bind to self proteins.
This counter balance system is what is missing from aptamer selection. We can perform counter selection against the matrix, but this only effectively eliminates those aptamers that bind really strongly to a matrix component. Counter selection against serum albumin should theoretically be performed at the concentration that serum albumin is present in blood (600 uM). We do this by using serum directly in counter selection with our FRELEX approach, or by immobilizing all of the protein in blood on UltraLink resin.
Our new Neomer selection platform represents the addition of a counter-balancing system to weed out all aptamers that bind, even weakly, to counter targets. With the Neomer system we are able to catalogue aptamer sequences that bind to dominant counter targets like HSA and IgG, and remove them as candidate sequences.
To learn more about the Neomer aptamer selection method please:
Or reach out by email to info@neoventures.ca
El Dr. Gregory Penner recibió una formación académica que combinaba teoría muy práctica de mejoramiento de plantas con biología molecular. Ha utilizado esta combinación de biología y matemáticas para desarrollar y liderar primero un equipo de investigación en biotecnología de cereales con el gobierno de Canadá y posteriormente como líder de investigación global en Monsanto Inc. Ha sido un líder de pensamiento en el desarrollo de aptámeros a nivel mundial durante los últimos veinte años como CEO y Presidente de NeoVentures. Ha llevado a esta empresa a una estabilidad financiera sin inversión externa con un enfoque integrado en el descubrimiento y comercialización de aptámeros. En 2015, cofundó una segunda empresa, NeoNeuro en París, Francia, centrada en un enfoque innovador para identificar Aptamarcadores para enfermedades complejas.
Conéctate con el Dr. Penner en LinkedIn Para actualizaciones de la compañía, sigue: NeoVentures.
Spanish 
English 
French